glp-1 obesity drug study august 2025 Market 2024 was a record year

However, a drawback of these medicines has been the necessity for administration by subcutaneous injection, which limits patient utilization and may reduce opportunities for fixed-dose combination treatments with other small-molecule drugs

The endocrinology market is witnessing impressive growth it is growing at a compound annual growth rate (CAGR) of 7.82 percent

MN = multinational

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment with SodiumGlucose Cotransporter 2 Inhibition

Fortunately, no tachyphylaxis was observed

The outcome data in T1DM is very limited and more data is needed #SGLT2inhibitors #GLP1receptoragonist #SGLT2i #GLP1 #nsMRA #nonsteroidalmineralocorticoidreceptorantagonists #CVcomplications #DKD #cardioprotection #nephroprotection #combinationtherapy To view or add a comment, sign in More Relevant Posts Superior to Skyrizi